{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:38:32Z","timestamp":1791405512241,"version":"4.3.3"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1038\/nrneurol.2009.217","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T02:14:23Z","timestamp":1265595263000},"page":"78-87","source":"Crossref","is-referenced-by-count":396,"title":["The use of PET in Alzheimer disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Agneta","family":"Nordberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha O.","family":"Rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmadul","family":"Kadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"L\u00e5ngstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrneurol2009217_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer, R., Johnson, E., Ziegler-Graha, K. & Arrighi, H. M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186\u2013191 (2007).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2009217_CR2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791\u20131800 (2002).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nature02621","volume":"430","author":"MP Mattson","year":"2004","unstructured":"Mattson, M. P. Pathways towards and away from Alzheimer's disease. Nature 430, 631\u2013639 (2004).","journal-title":"Nature"},{"key":"BFnrneurol2009217_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS\u2013ADRDA criteria. Lancet Neurol. 6, 734\u2013746 (2007).","journal-title":"Lancet Neurol."},{"issue":"Spec. No. 2","key":"BFnrneurol2009217_CR5","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1259\/bjr\/97295129","volume":"80","author":"K Herholz","year":"2007","unstructured":"Herholz, K., Carter, S. F. & Jones, M. Positron emission tomography imaging in dementia. Br. J. Radiol. 80 (Spec. No. 2), S160\u2013S167 (2007).","journal-title":"Br. J. Radiol."},{"key":"BFnrneurol2009217_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1474-4422(08)70019-X","volume":"7","author":"GW Small","year":"2008","unstructured":"Small, G. W. et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 7, 161\u2013172 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2009217_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","volume":"36","author":"L Mosconi","year":"2009","unstructured":"Mosconi, L. et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811\u2013822 (2009).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrneurol2009217_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","volume":"32","author":"L Mosconi","year":"2005","unstructured":"Mosconi, L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486\u2013510 (2005).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrneurol2009217_CR9","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/brain\/awl178","volume":"129","author":"H Engler","year":"2006","unstructured":"Engler, H. et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856\u20132866 (2006).","journal-title":"Brain"},{"key":"BFnrneurol2009217_CR10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1212\/01.wnl.0000269790.05105.16","volume":"69","author":"W Jagust","year":"2007","unstructured":"Jagust, W., Reed, B., Mungas, D., Ellis, W. & Decarli, C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871\u2013877 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR11","first-page":"1625","volume":"46","author":"A Drzezga","year":"2005","unstructured":"Drzezga, A. et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J. Nucl. Med. 46, 1625\u20131632 (2005).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s00259-003-1194-1","volume":"30","author":"A Drzezga","year":"2003","unstructured":"Drzezga, A. et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 30, 1104\u20131113 (2003).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrneurol2009217_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.exger.2006.05.016","volume":"42","author":"L Mosconi","year":"2007","unstructured":"Mosconi, L. et al. Early detection of Alzheimer's disease using neuroimaging. Exp. Gerontol. 42, 129\u2013138 (2007).","journal-title":"Exp. Gerontol."},{"key":"BFnrneurol2009217_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(94)92871-1","volume":"344","author":"S Minoshima","year":"1994","unstructured":"Minoshima, S., Foster, N. L. & Kuhl, D. E. Posterior cingulate cortex in Alzheimer's disease. Lancet 344, 895 (1994).","journal-title":"Lancet"},{"key":"BFnrneurol2009217_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ana.410420114","volume":"42","author":"S Minoshima","year":"1997","unstructured":"Minoshima, S. et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85\u201394 (1997).","journal-title":"Ann. Neurol."},{"issue":"8","key":"BFnrneurol2009217_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.neurobiolaging.2009.08.016","volume":"32","author":"Michael Sch\u00f6ll","year":"2011","unstructured":"Sch\u00f6ll, M. et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol. Aging doi:10.1016\/j.neurobiolaging.2009.08.016.","journal-title":"Neurobiology of Aging"},{"key":"BFnrneurol2009217_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1073\/pnas.2635903100","volume":"101","author":"EM Reiman","year":"2004","unstructured":"Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101, 284\u2013289 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009217_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jama.1995.03520360056039","volume":"273","author":"GW Small","year":"1995","unstructured":"Small, G. W. et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942\u2013947 (1995).","journal-title":"JAMA"},{"key":"BFnrneurol2009217_CR19","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.061509598","volume":"98","author":"EM Reiman","year":"2001","unstructured":"Reiman, E. M. et al. Declining brain activity in cognitively normal apolipoprotein E \u03b54 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 3334\u20133339 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009217_CR20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJM199603213341202","volume":"334","author":"EM Reiman","year":"1996","unstructured":"Reiman, E. M. et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the \u03b54 allele for apolipoprotein E. N. Engl. J. Med. 334, 752\u2013758 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2009217_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/ana.10999","volume":"55","author":"NL Pedersen","year":"2004","unstructured":"Pedersen, N. L., Gatz, M., Berg, S. & Johansson, B. How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann. Neurol. 55, 180\u2013185 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000072809","volume":"16","author":"T J\u00e4rvenp\u00e4\u00e4","year":"2003","unstructured":"J\u00e4rvenp\u00e4\u00e4, T. et al. Regional cerebral glucose metabolism in monozygotic twins discordant for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 16, 245\u2013252 (2003).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrneurol2009217_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/jnnp.2008.145466","volume":"80","author":"JJ Virta","year":"2009","unstructured":"Virta, J. J. et al. Voxel-based analysis of cerebral glucose metabolism in mono- and dizygotic twins discordant for Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80, 259\u2013266 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2009217_CR24","doi-asserted-by":"publisher","first-page":"19067","DOI":"10.1073\/pnas.0705036104","volume":"104","author":"L Mosconi","year":"2007","unstructured":"Mosconi, L. et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl Acad. Sci. USA 104, 19067\u201319072 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009217_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0079-6123(08)64021-2","volume":"117","author":"H Braak","year":"1998","unstructured":"Braak, H., de Vos, R. A., Jansen, E. N., Bratzke, H. & Braak, E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res. 117, 267\u2013285 (1998).","journal-title":"Prog. Brain Res."},{"key":"BFnrneurol2009217_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2990.1978.tb00545.x","volume":"4","author":"EK Perry","year":"1978","unstructured":"Perry, E. K., Perry, R. H., Blessed, G. & Tomlinson, B. E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 4, 273\u2013277 (1978).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"BFnrneurol2009217_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp.74.1.113","volume":"74","author":"JO Rinne","year":"2003","unstructured":"Rinne, J. O. et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 113\u2013115 (2003).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2009217_CR28","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/01.wnr.0000177007.21732.7b","volume":"16","author":"K Herholz","year":"2005","unstructured":"Herholz, K., Weisenbach, S., Kalbe, E., Diederich, N. J. & Heiss, W. D. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 16, 1431\u20131434 (2005).","journal-title":"Neuroreport"},{"key":"BFnrneurol2009217_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0301-0082(99)00045-3","volume":"61","author":"D Paterson","year":"2000","unstructured":"Paterson, D. & Nordberg, A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61, 75\u2013111 (2000).","journal-title":"Prog. Neurobiol."},{"key":"BFnrneurol2009217_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00213-006-0447-7","volume":"188","author":"A Kadir","year":"2006","unstructured":"Kadir, A., Almkvist, O., Wall, A., L\u00e5ngstr\u00f6m, B. & Nordberg, A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl.) 188, 509\u2013520 (2006).","journal-title":"Psychopharmacology (Berl.)"},{"issue":"15-16","key":"BFnrneurol2009217_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.lfs.2009.02.029","volume":"86","author":"Andrew G. Horti","year":"2010","unstructured":"Horti, A. G., Gao, Y., Kuwabara, H. & Dannals, R. F. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci. doi:10.1016\/j.lfs.2009.02.029.","journal-title":"Life Sciences"},{"issue":"Suppl. 1","key":"BFnrneurol2009217_CR32","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1007\/s00259-007-0701-1","volume":"35","author":"O Sabri","year":"2008","unstructured":"Sabri, O., Kendziorra, K., Wolf, H., Gertz, H. J. & Brust, P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 35 (Suppl. 1), S30\u2013S45 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrneurol2009217_CR33","first-page":"326","volume":"46","author":"MG Pomper","year":"2005","unstructured":"Pomper, M. G. et al. Synthesis and biodistribution of radiolabeled \u03b17 nicotinic acetylcholine receptor ligands. J. Nucl. Med. 46, 326\u2013334 (2005).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12149-009-0240-x","volume":"23","author":"J Toyohara","year":"2009","unstructured":"Toyohara, J. et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping \u03b17 nicotinic receptors by positron emission tomography. Ann. Nucl. Med. 23, 301\u2013309 (2009).","journal-title":"Ann. Nucl. Med."},{"key":"BFnrneurol2009217_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1098-2396(20010315)39:4<275::AID-SYN1010>3.0.CO;2-3","volume":"39","author":"JK Zubieta","year":"2001","unstructured":"Zubieta, J. K. et al. Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse 39, 275\u2013287 (2001).","journal-title":"Synapse"},{"key":"BFnrneurol2009217_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/syn.10225","volume":"49","author":"RM Cohen","year":"2003","unstructured":"Cohen, R. M. et al. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-\u03b54 allele. Synapse 49, 150\u2013156 (2003).","journal-title":"Synapse"},{"key":"BFnrneurol2009217_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/jnr.490270419","volume":"27","author":"KJ Reinikainen","year":"1990","unstructured":"Reinikainen, K. J., Soininen, H. & Riekkinen, P. J. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J. Neurosci. Res. 27, 576\u2013586 (1990).","journal-title":"J. Neurosci. Res."},{"key":"BFnrneurol2009217_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1212\/WNL.50.1.152","volume":"50","author":"JO Rinne","year":"1998","unstructured":"Rinne, J. O., Sahlberg, N., Ruottinen, H., Nagren, K. & Lehikoinen, P. Striatal uptake of the dopamine reuptake ligand [11C]\u03b2-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 50, 152\u2013156 (1998).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/jnnp.73.2.134","volume":"73","author":"Z Walker","year":"2002","unstructured":"Walker, Z. et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J. Neurol. Neurosurg. Psychiatry 73, 134\u2013140 (2002).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2009217_CR40","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith, I. et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 6, 305\u2013313 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2009217_CR41","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","volume":"78","author":"Z Walker","year":"2007","unstructured":"Walker, Z. et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J. Neurol. Neurosurg. Psychiatry 78, 1176\u20131181 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2009217_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1212\/WNL.55.2.205","volume":"55","author":"N Kemppainen","year":"2000","unstructured":"Kemppainen, N., Ruottinen, H., N\u00e5gren, K. & Rinne, J. O. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 55, 205\u2013209 (2000).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/BF03006670","volume":"17","author":"Y Tanaka","year":"2003","unstructured":"Tanaka, Y. et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann. Nucl. Med. 17, 567\u2013573 (2003).","journal-title":"Ann. Nucl. Med."},{"key":"BFnrneurol2009217_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1460-9568.2003.02716.x","volume":"18","author":"N Kemppainen","year":"2003","unstructured":"Kemppainen, N. et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur. J. Neurosci. 18, 149\u2013154 (2003).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrneurol2009217_CR45","first-page":"303","volume":"4","author":"A Nordberg","year":"1992","unstructured":"Nordberg, A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain. Metab. Rev. 4, 303\u2013328 (1992).","journal-title":"Cerebrovasc. Brain. Metab. Rev."},{"key":"BFnrneurol2009217_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1073\/pnas.0510237103","volume":"103","author":"V Kepe","year":"2006","unstructured":"Kepe, V. et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc. Natl Acad. Sci. USA 103, 702\u2013707 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009217_CR47","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1176\/ajp.156.12.1871","volume":"156","author":"CC Meltzer","year":"1999","unstructured":"Meltzer, C. C. et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry 156, 1871\u20131878 (1999).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrneurol2009217_CR48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/WCO.0b013e32832d93c7","volume":"22","author":"W Jagust","year":"2009","unstructured":"Jagust, W. Mapping brain \u03b2-amyloid. Curr. Opin. Neurol. 22, 356\u2013361 (2009).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrneurol2009217_CR49","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306\u2013319 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR50","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1523\/JNEUROSCI.2990-05.2005","volume":"25","author":"WE Klunk","year":"2005","unstructured":"Klunk, W. E. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-\u03b2 in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598\u201310606 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2009217_CR51","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic, M. D. et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 1630\u20131645 (2008).","journal-title":"Brain"},{"key":"BFnrneurol2009217_CR52","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/archneur.65.10.noc80013","volume":"65","author":"V Leinonen","year":"2008","unstructured":"Leinonen, V. et al. Assessment of \u03b2-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch. Neurol. 65, 1304\u20131309 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2009217_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.neuint.2008.12.016","volume":"54","author":"MM Svedberg","year":"2009","unstructured":"Svedberg, M. M. et al. [11C]PIB-amyloid binding and levels of A\u03b240 and A\u03b242 in postmortem brain tissue from Alzheimer patients. Neurochem. Int. 54, 347\u2013357 (2009).","journal-title":"Neurochem. Int."},{"key":"BFnrneurol2009217_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.20889","volume":"60","author":"HA Archer","year":"2006","unstructured":"Archer, H. A. et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann. Neurol. 60, 145\u2013147 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR55","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1212\/01.wnl.0000240117.55680.0a","volume":"67","author":"NM Kemppainen","year":"2006","unstructured":"Kemppainen, N. M. et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67, 1575\u20131580 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR56","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446\u2013452 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR57","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","volume":"25","author":"JC Price","year":"2005","unstructured":"Price, J. C. et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 25, 1528\u20131547 (2005).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"BFnrneurol2009217_CR58","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe, C. C. et al. Imaging \u03b2-amyloid burden in aging and dementia. Neurology 68, 1718\u20131725 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR59","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg, A. et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 1456\u20131465 (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009217_CR60","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack Jr","year":"2009","unstructured":"Jack, C. R. Jr et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355\u20131365 (2009).","journal-title":"Brain"},{"key":"BFnrneurol2009217_CR61","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1212\/01.wnl.0000260969.94695.56","volume":"68","author":"NM Kemppainen","year":"2007","unstructured":"Kemppainen, N. M. et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68, 1603\u20131606 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR62","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike, K. E. et al. \u03b2-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837\u20132844 (2007).","journal-title":"Brain"},{"key":"BFnrneurol2009217_CR63","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello, A. et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73, 754\u2013760 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR64","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/ana.21598","volume":"65","author":"DA Wolk","year":"2009","unstructured":"Wolk, D. A. et al. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 65, 557\u2013568 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR65","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2967\/jnumed.108.058529","volume":"50","author":"VJ Lowe","year":"2009","unstructured":"Lowe, V. J. et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 50, 878\u2013886 (2009).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR66","unstructured":"Forsberg, A. et al. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr. Alzheimer Res. doi:10.2174\/1567210198607192050."},{"key":"BFnrneurol2009217_CR67","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann. Neurol. 59, 512\u2013519 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR68","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000163927","volume":"26","author":"J Koivunen","year":"2008","unstructured":"Koivunen, J. et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 26, 378\u2013383 (2008).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrneurol2009217_CR69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison, P. et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68, 501\u2013508 (2007).","journal-title":"Neurology"},{"issue":"7","key":"BFnrneurol2009217_CR70","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"Susan M. Landau","year":"2011","unstructured":"Landau, S. M. et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging doi:10.1016\/j.neurobiolaging.2009.07.002.","journal-title":"Neurobiology of Aging"},{"key":"BFnrneurol2009217_CR71","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.neurobiolaging.2008.01.016","volume":"30","author":"T Grimmer","year":"2008","unstructured":"Grimmer, T. et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol. Aging 30, 1902\u20131909 (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009217_CR72","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","volume":"46","author":"VL Villemagne","year":"2008","unstructured":"Villemagne, V. L. et al. A\u03b2 deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688\u20131697 (2008).","journal-title":"Neuropsychologia"},{"key":"BFnrneurol2009217_CR73","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.0b013e3181a2e8d0","volume":"72","author":"A Drzezga","year":"2009","unstructured":"Drzezga, A. et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487\u20131494 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR74","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman, E. M. et al. Fibrillar amyloid-\u03b2 burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 6820\u20136825 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009217_CR75","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/WNL.0b013e3181bacf1b","volume":"73","author":"NM Scheinin","year":"2009","unstructured":"Scheinin, N. M. et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 73, 1186\u20131192 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR76","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","volume":"79","author":"P Edison","year":"2008","unstructured":"Edison, P. et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79, 1331\u20131338 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2009217_CR77","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.parkreldis.2007.07.010","volume":"14","author":"A Johansson","year":"2008","unstructured":"Johansson, A. et al. [11C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat. Disord. 14, 345\u2013347 (2008).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrneurol2009217_CR78","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.neuroimage.2007.09.072","volume":"39","author":"W Maetzler","year":"2008","unstructured":"Maetzler, W. et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39, 1027\u20131033 (2008).","journal-title":"Neuroimage"},{"key":"BFnrneurol2009217_CR79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.neuroimage.2007.09.020","volume":"39","author":"A Drzezga","year":"2008","unstructured":"Drzezga, A. et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 39, 619\u2013633 (2008).","journal-title":"Neuroimage"},{"key":"BFnrneurol2009217_CR80","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00259-007-0523-1","volume":"35","author":"H Engler","year":"2008","unstructured":"Engler, H. et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging 35, 100\u2013106 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrneurol2009217_CR81","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","volume":"71","author":"SN Gomperts","year":"2008","unstructured":"Gomperts, S. N. et al. Imaging amyloid deposition in Lewy body diseases. Neurology 71, 903\u2013910 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR82","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ana.21164","volume":"62","author":"KA Johnson","year":"2007","unstructured":"Johnson, K. A. et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 62, 229\u2013234 (2007).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR83","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein, H. J. et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509\u20131517 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2009217_CR84","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMoa054625","volume":"355","author":"GW Small","year":"2006","unstructured":"Small, G. W. et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355, 2652\u20132663 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2009217_CR85","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jns.2009.06.005","volume":"285","author":"M Waragai","year":"2009","unstructured":"Waragai, M. et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. J. Neurol. Sci. 285, 100\u2013108 (2009).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2009217_CR86","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe, C. C. et al. Imaging of amyloid \u03b2 in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7, 129\u2013135 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2009217_CR87","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2967\/jnumed.108.056499","volume":"50","author":"N Tolboom","year":"2009","unstructured":"Tolboom, N. et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J. Nucl. Med. 50, 191\u2013197 (2009).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR88","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1471-4159.2009.05996.x","volume":"109","author":"PW Thompson","year":"2009","unstructured":"Thompson, P. W. et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem. 109, 623\u2013630 (2009).","journal-title":"J. Neurochem."},{"key":"BFnrneurol2009217_CR89","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid, K. et al. Localization of neurofibrillary tangles and \u03b2-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24\u201335 (2002).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrneurol2009217_CR90","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","volume":"101","author":"DM Walsh","year":"2007","unstructured":"Walsh, D. M. & Selkoe, D. J. A\u03b2 oligomers\u2014a decade of discovery. J. Neurochem. 101, 1172\u20131184 (2007).","journal-title":"J. Neurochem."},{"key":"BFnrneurol2009217_CR91","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(01)05625-2","volume":"358","author":"A Cagnin","year":"2001","unstructured":"Cagnin, A. et al. In-vivo measurement of activated microglia in dementia. Lancet 358, 461\u2013467 (2001).","journal-title":"Lancet"},{"key":"BFnrneurol2009217_CR92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1212\/01.wnl.0000338622.27876.0d","volume":"72","author":"A Okello","year":"2009","unstructured":"Okello, A. et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72, 56\u201362 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR93","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/archneurol.2008.511","volume":"66","author":"CA Wiley","year":"2009","unstructured":"Wiley, C. A. et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch. Neurol. 66, 60\u201367 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2009217_CR94","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11010-008-0012-2","volume":"326","author":"V Hirsch-Reinshagen","year":"2009","unstructured":"Hirsch-Reinshagen, V., Burgess, B. L. & Wellington, C. L. Why lipids are important for Alzheimer disease? Mol. Cell Biochem. 326, 121\u2013129 (2009).","journal-title":"Mol. Cell Biochem."},{"key":"BFnrneurol2009217_CR95","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.neurobiolaging.2007.02.020","volume":"29","author":"A Kadir","year":"2008","unstructured":"Kadir, A. et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol. Aging 29, 1204\u20131217 (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009217_CR96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/jnnp.2004.038729","volume":"76","author":"NI Bohnen","year":"2005","unstructured":"Bohnen, N. I. et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 76, 315\u2013319 (2005).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2009217_CR97","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","volume":"48","author":"DE Kuhl","year":"2000","unstructured":"Kuhl, D. E. et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol. 48, 391\u2013395 (2000).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR98","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00004714-200212000-00012","volume":"22","author":"V Kaasinen","year":"2002","unstructured":"Kaasinen, V. et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. 22, 615\u2013620 (2002).","journal-title":"J. Clin. Psychopharmacol."},{"key":"BFnrneurol2009217_CR99","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1212\/WNL.56.3.408","volume":"56","author":"H Shinotoh","year":"2001","unstructured":"Shinotoh, H. et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 56, 408\u2013410 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol2009217_CR100","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00213-007-0725-z","volume":"191","author":"A Kadir","year":"2007","unstructured":"Kadir, A. et al. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl.) 191, 1005\u20131014 (2007).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnrneurol2009217_CR101","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00213-008-1347-9","volume":"202","author":"JR Ellis","year":"2009","unstructured":"Ellis, J. R. et al. Galantamine-induced improvements in cognitive function are not related to alterations in \u03b14\u03b22 nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. Psychopharmacology (Berl.) 202, 79\u201391 (2009).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnrneurol2009217_CR102","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000095624","volume":"22","author":"J Diehl-Schmid","year":"2006","unstructured":"Diehl-Schmid, J. et al. Longitudinal changes of cerebral glucose metabolism in semantic dementia. Dement. Geriatr. Cogn. Disord. 22, 346\u2013351 (2006).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrneurol2009217_CR103","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2005.11.002","volume":"28","author":"J Diehl-Schmid","year":"2007","unstructured":"Diehl-Schmid, J. et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol. Aging 28, 42\u201350 (2007).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2009217_CR104","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1602\/neurorx.2.2.348","volume":"2","author":"BC Dickerson","year":"2005","unstructured":"Dickerson, B. C. & Sperling, R. A. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2, 348\u2013360 (2005).","journal-title":"NeuroRx"},{"issue":"Suppl. 1","key":"BFnrneurol2009217_CR105","first-page":"S29","volume":"4","author":"NL Foster","year":"2008","unstructured":"Foster, N. L. et al. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement. 4 (Suppl. 1), S29\u2013S36 (2008).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2009217_CR106","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/00019442-200303000-00005","volume":"11","author":"B Matthews","year":"2003","unstructured":"Matthews, B., Siemers, E. R. & Mozley, P. D. Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am. J. Geriatr. Psychiatry 11, 146\u2013159 (2003).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrneurol2009217_CR107","first-page":"63","volume":"14","author":"MS Mega","year":"2001","unstructured":"Mega, M. S. et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 14, 63\u201368 (2001).","journal-title":"Neuropsychiatry Neuropsychol. Behav. Neurol."},{"key":"BFnrneurol2009217_CR108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00702-005-0312-6","volume":"113","author":"E Stefanova","year":"2006","unstructured":"Stefanova, E. et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J. Neural Transm. 113, 205\u2013218 (2006).","journal-title":"J. Neural Transm."},{"key":"BFnrneurol2009217_CR109","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00019442-200303000-00007","volume":"11","author":"L Tune","year":"2003","unstructured":"Tune, L. et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am. J. Geriatr. Psychiatry 11, 169\u2013177 (2003).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrneurol2009217_CR110","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/archneur.62.5.721","volume":"62","author":"MS Mega","year":"2005","unstructured":"Mega, M. S. et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F 18 positron emission tomographic study. Arch. Neurol. 62, 721\u2013728 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2009217_CR111","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00213-006-0408-1","volume":"187","author":"SJ Teipel","year":"2006","unstructured":"Teipel, S. J. et al. Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl.) 187, 86\u201394 (2006).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnrneurol2009217_CR112","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ana.21345","volume":"63","author":"A Kadir","year":"2008","unstructured":"Kadir, A. et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann. Neurol. 63, 621\u2013631 (2008).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2009217_CR113","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/brain\/awn326","volume":"132","author":"GS Smith","year":"2009","unstructured":"Smith, G. S. et al. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain 132, 392\u2013401 (2009).","journal-title":"Brain"},{"key":"BFnrneurol2009217_CR114","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm1239","volume":"11","author":"MH Tuszynski","year":"2005","unstructured":"Tuszynski, M. H. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551\u2013555 (2005).","journal-title":"Nat. Med."},{"key":"BFnrneurol2009217_CR115","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000017069","volume":"9","author":"M Eriksdotter Jonhagen","year":"1998","unstructured":"Eriksdotter Jonhagen, M. et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9, 246\u2013257 (1998).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrneurol2009217_CR116","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/jpet.106.112102","volume":"320","author":"DK Lahiri","year":"2007","unstructured":"Lahiri, D. K. et al. The experimental Alzheimer's disease drug posiphen[(+)-phenserine] lowers amyloid-\u03b2 peptide levels in cell culture and mice. J. Pharmacol. Exp. Ther. 320, 386\u2013396 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrneurol2009217_CR117","doi-asserted-by":"publisher","first-page":"12506","DOI":"10.1073\/pnas.0705346104","volume":"104","author":"A Marutle","year":"2007","unstructured":"Marutle, A. et al. Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc. Natl Acad. Sci. USA 104, 12506\u201312511 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2009217_CR118","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2967\/jnmt.108.054296","volume":"37","author":"P Razifar","year":"2009","unstructured":"Razifar, P. et al. An automated method for delineating a reference region using masked volumewise principal-component analysis in 11C-PIB PET. J. Nucl. Med. Technol. 37, 38\u201344 (2009).","journal-title":"J. Nucl. Med. Technol."},{"key":"BFnrneurol2009217_CR119","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2377-9-2","volume":"9","author":"P Razifar","year":"2009","unstructured":"Razifar, P., Ringheim, A., Engler, H., Hall, H. & L\u00e5ngstr\u00f6m, B. Masked-volume-wise PCA and \u201creference Logan\u201d illustrate similar regional differences in kinetic behavior in human brain PET study using [11C]-PIB. BMC Neurol. 9, 2 (2009).","journal-title":"BMC Neurol."},{"key":"BFnrneurol2009217_CR120","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/WCO.0b013e3281a47744","volume":"20","author":"A Nordberg","year":"2007","unstructured":"Nordberg, A. Amyloid imaging in Alzheimer's disease. Curr. Opin. Neurol. 20, 398\u2013402 (2007).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrneurol2009217_CR121","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"BFnrneurol2009217_CR122","first-page":"2032","volume":"45","author":"A Roivainen","year":"2004","unstructured":"Roivainen, A. et al. Biodistribution and blood metabolism of 1-11C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET. J. Nucl. Med. 45, 2032\u20132039 (2004).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR123","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen, N. et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 50, 1251\u20131259 (2009).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR124","first-page":"584","volume":"12","author":"NP Verhoeff","year":"2004","unstructured":"Verhoeff, N. P. et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12, 584\u2013595 (2004).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrneurol2009217_CR125","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2967\/jnumed.106.037556","volume":"48","author":"Y Kudo","year":"2007","unstructured":"Kudo, Y. et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48, 553\u2013561 (2007).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR126","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","volume":"50","author":"SR Choi","year":"2009","unstructured":"Choi, S. R. et al. Preclinical properties of 18F-AV-45: a PET agent for A\u03b2 plaques in the brain. J. Nucl. Med. 50, 1887\u20131894 (2009).","journal-title":"J. Nucl. Med."},{"key":"BFnrneurol2009217_CR127","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00259-009-1182-1","volume":"36","author":"S Nyberg","year":"2009","unstructured":"Nyberg, S. et al. Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur. J. Nucl. Med. Mol. Imaging 36, 1859\u20131863 (2009).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.217","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:14:14Z","timestamp":1685405654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2009.217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":127,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["BFnrneurol2009217"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2009.217","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}